Novartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet the primary endpoint of sustained remission at week 52 for a new indication ...

Novartis (NYSE:NVS) (OTCPK:NVSEF) announced Thursday that its FDA-approved anti-inflammatory agent Cosentyx failed to reach the main goal in a Phase 3 trial for adults with giant cell arteritis ((GCA) ...

(RTTNews) - Novartis (NVS,NOVN.SW) announced that its interleukin-17A inhibitor Cosentyx (secukinumab) met the primary and all secondary endpoints in the Phase III REPLENISH trial. The study evaluated ...

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx™ (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes ...

Medicine company Novartis (NVS) said on Thursday that a late-stage trial evaluating its drug Cosentyx in adults with newly diagnosed or relapsing giant cell arteritis failed to meet its primary goal ...

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx ™ (secukinumab) in Europe to treat ankylosing spondylitis (AS) and ...

Polymyalgia rheumatica is the second most common inflammatory rheumatic disease in adults aged 50 years and older, typically characterized by acute pain and stiffness in the shoulders, neck, and hips.

Important milestone towards public reimbursement for a new treatment option for eligible Canadian patients living with moderate to severe hidradenitis suppurativa (HS) Following this important ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in November. The drug’s manufacturer, Novartis, said Sept.

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections to treat several inflammatory conditions. Adults and certain children can receive this medication to treat ...

Novartis said it is launching a direct-to-patient platform in the U.S. to sell a discounted version of its Cosentyx drug, the latest big pharma company to move to cut prices ahead of the Trump ...